Antiangiogenic and immune checkpoint therapies as first-line treatment have been shown to improve outcomes in patients with advanced clear-cell renal-cell carcinoma. 1-5 After disease progression ...

Inactivation of the von Hippel–Lindau (VHL) tumor-suppressor protein characterizes clear-cell tumors, the predominant histologic subtype in patients with renal-cell carcinoma, and results in the ...

Everolimus as second-line therapy for metastatic renal cell carcinoma (mRCC) after one previous VEGF-targeted therapy: Final results of the noninterventional change study. Authors : Peter J. Goebell , ...

Everolimus (Afinitor, Novartis) is not as effective as sunitinib (Sutent, Pfizer) in the first-line setting for patients with metastatic renal cell carcinoma, and it has a different toxicity ...

Background: For patients (pts) with recurrent or stage IV non-clear cell renal cancer (nccRCC),the medical treatment guidelines recommend the first choice to participate in clinical trials, or use TKI ...

Treatment of everolimus-resistant disease remains largely undefined in metastatic renal cell carcinoma (mRCC). We report on 40 patients (pts) who receive systemic treatment after failure of ...

Grünwald V, Seidel C, Fenner M, Ganser A, Busch J, Weikert S. (2011) Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies. Br J Cancer 105 (11): 1635–1639 ...

Everolimus, an investigational mTor inhibitor, improved survival in patients with metastatic renal cell carcinoma whose disease had progressed after treatment with sunitinib and/or sorafenib.

3.2 According to the marketing authorisation, lenvatinib plus everolimus is indicated for advanced renal cell carcinoma after 1 previous vascular endothelial growth factor (VEGF)-targeted therapy. The ...

This guidance is a Cancer Drugs Fund reconsideration of everolimus for the second-line treatment of advanced renal cell carcinoma (TA219). This guidance replaces TA219. Next review: This guidance will ...

Renal cell carcinoma develops in the lining of the ... and fourth-line therapies. 3 Stage 4 renal cell carcinoma is incurable in most ... Lenvatinib plus everolimus (second to sunitinib, ...

Belzutifan significantly improved PFS and objective response compared with everolimus for patients with advanced renal cell carcinoma, according to results of a randomized phase 3 trial ...